Last reviewed · How we verify
IFENPRODIL
IFENPRODIL is a ifenprodil drug. It is currently in Phase 2 development.
IFENPRODIL works by selectively blocking the Sigma non-opioid intracellular receptor 1.
IFENPRODIL is a small molecule drug class ifenprodil that targets the Sigma non-opioid intracellular receptor 1. It is currently owned by an unknown entity, and its original development is attributed to an unspecified company. IFENPRODIL's commercial status, including FDA approval and generic availability, is unknown. As a result, its approved indications and off-patent status are also unclear. Key safety considerations include its half-life of 4.32 hours.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IFENPRODIL |
|---|---|
| Drug class | ifenprodil |
| Target | Glutamate receptor ionotropic, NMDA 2A, Glutamate receptor ionotropic, NMDA 2B, Glutamate receptor ionotropic, NMDA 2C |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of it like a key fitting into a lock. IFENPRODIL is the key that blocks the Sigma receptor, which can help reduce pain and other symptoms. This blocking action helps to modulate the receptor's activity, leading to therapeutic effects.
Approved indications
Common side effects
Key clinical trials
- Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis (PHASE2)
- Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough (PHASE2)
- Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease (PHASE2,PHASE3)
- Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IFENPRODIL CI brief — competitive landscape report
- IFENPRODIL updates RSS · CI watch RSS
Frequently asked questions about IFENPRODIL
What is IFENPRODIL?
How does IFENPRODIL work?
What drug class is IFENPRODIL in?
What development phase is IFENPRODIL in?
What does IFENPRODIL target?
Related
- Drug class: All ifenprodil drugs
- Target: All drugs targeting Glutamate receptor ionotropic, NMDA 2A, Glutamate receptor ionotropic, NMDA 2B, Glutamate receptor ionotropic, NMDA 2C
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing